Ubs Group Ag Century Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 22,291 shares of IPSC stock, worth $23,182. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,291

Previous 14,095 58.15%

Holding current value

$23,182

Previous $35,000 8.57%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.44 - $3.29 $11,802 - $26,964	8,196 Added 58.15%	22,291 $38,000
Q2 2024 Aug 13, 2024	SELL	$2.46 - $4.05 $35,972 - $59,223	-14,623 Reduced 50.92%	14,095 $35,000
Q1 2024 May 13, 2024	BUY	$3.19 - $5.32 $9,968 - $16,625	3,125 Added 12.21%	28,718 $120,000
Q4 2023 Feb 09, 2024	BUY	$1.28 - $3.32 $11,345 - $29,428	8,864 Added 52.99%	25,593 $84,000
Q3 2023 Nov 09, 2023	BUY	$2.0 - $3.23 $5,430 - $8,769	2,715 Added 19.37%	16,729 $33,000
Q2 2023 Aug 11, 2023	BUY	$2.91 - $3.53 $19,430 - $23,569	6,677 Added 91.0%	14,014 $44,000
Q1 2023 May 12, 2023	BUY	$3.4 - $5.11 $6,405 - $9,627	1,884 Added 34.55%	7,337 $25,000
Q4 2022 Feb 08, 2023	BUY	$4.84 - $11.58 $26,392 - $63,145	5,453 New	5,453 $27,000
Q2 2022 Aug 10, 2022	SELL	$7.96 - $12.43 $254 - $397	-32 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$11.62 - $15.92 $63,863 - $87,496	-5,496 Reduced 99.42%	32 $0
Q4 2021 Feb 14, 2022	BUY	$13.93 - $23.62 $70,290 - $119,186	5,046 Added 1046.89%	5,528 $88,000
Q3 2021 Nov 15, 2021	SELL	$20.8 - $31.93 $11,440 - $17,561	-550 Reduced 53.29%	482 $12,000
Q2 2021 Aug 13, 2021	BUY	$22.45 - $29.34 $23,168 - $30,278	1,032 New	1,032 $30,000

Others Institutions Holding IPSC

# of Institutions

Shares Held

36.9M

Call Options Held

8.7K

Put Options Held

10.2K

View Full List

About Century Therapeutics, Inc.

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $61.2M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

More about IPSC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account